MedPath

Role of hydrocortisone and indomethacin in reducing major complications after Whipples pancreaticoduodenectomy

Phase 2
Conditions
Health Condition 1: C241- Malignant neoplasm of ampulla of VaterHealth Condition 2: C170- Malignant neoplasm of duodenumHealth Condition 3: C240- Malignant neoplasm of extrahepaticbile ductHealth Condition 4: C250- Malignant neoplasm of head of pancreasHealth Condition 5: K838- Other specified diseases of biliary tractHealth Condition 6: K868- Other specified diseases of pancreasHealth Condition 7: null- Patients undergoing Whipples Pancreaticoduodenectomy for relevant indications
Registration Number
CTRI/2018/06/014541
Lead Sponsor
ASIAN INSTITUTE OF GASTROENTEROLOGY
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Closed to Recruitment of Participants
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

•All patients undergoing Whippleâ??s PD in Asian Institute of Gastroenterology, Hyderabad

•Patients having >40% acini at cut surface of pancreas ( previous studies have shown that those patients in whom pancreas contain more number of acini are tend to have softer pancreas, more local inflammatory response and hence more chances of Anastomotic leak. Only those patients who are at high risk for leak i.e. more than 40% acini in cut surface of pancreas will be included in the study and recieve the remaining doses of drugs and followed up).

Exclusion Criteria

•On table - inoperable patients

•Patients already on steroid treatment

•Patients already on long term NSAIDs treatment

•Patients with Chronic pancreatitis (these patients are at low risk of leak due to hard texture of pancreas, hence will be excluded from the study)

•Patients of Chronic kidney disease

•Patients who suffered stroke or acute coronary syndrome in past

•Known case of peptic ulcer disease

•Patients having thrombocytopenia

•Patients not giving consent for participation

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
â?¢Major overall complication rate (Clavienâ??Dindo class II, III , IV & V)Timepoint: Upto 30 days after surgery
Secondary Outcome Measures
NameTimeMethod
â?¢Post operative pancreatic fistula rate <br/ ><br>â?¢Post pancreatectomy haemorrhage rate <br/ ><br>â?¢Delayed gastric emptying rate <br/ ><br>â?¢Surgical site infection rate <br/ ><br>â?¢Post operative drain fluid amylase on post operative day 3,5 and 7 (required to establish the diagnosis of pancreatic fistula) <br/ ><br>â?¢Days of drain removal (operatively placed drains are retained in the patients having pancreatic fistula) <br/ ><br>â?¢Number of days of ICU stay <br/ ><br>â?¢Overall days of hospitalization <br/ ><br>â?¢Re-admission rateTimepoint: Upto 30 days after surgery
© Copyright 2025. All Rights Reserved by MedPath